(Q46372426)

21 December 2017

title

Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients (English)

1 reference

21 December 2017

0 references

4

E Ferrannini

1 reference

21 December 2017

author name string

E Santini

1

1 reference

21 December 2017

S Madec

2

1 reference

21 December 2017

V Corretti

3

1 reference

21 December 2017

A Solini

5

1 reference

21 December 2017

publication date

1 July 2008

1 reference

21 December 2017

Journal of Endocrinological Investigation

published in

1 reference

21 December 2017

volume

31

1 reference

21 December 2017

issue

7

1 reference

21 December 2017

page(s)

660-665

1 reference

21 December 2017

Dyslipidaemia, hypercoagulability and the metabolic syndrome

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Platelet function, coagulopathy, and impaired fibrinolysis in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Inflammation and the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

The CD40/CD154 receptor/ligand dyad

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Soluble CD40L: risk prediction after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Simvastatin prevents vascular hyporeactivity during inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Statins: potential new indications in inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Soluble CD40 Ligand in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345621

Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients.

21 January 2018

1 reference

12 December 2020

Inflammation as a cardiovascular risk factor

1 reference

12 December 2020

Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes

1 reference

12 December 2020

Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection

1 reference

12 December 2020

Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats

1 reference

12 December 2020

Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels

1 reference

12 December 2020

Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover

1 reference

12 December 2020

Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?

1 reference

12 December 2020

1 reference

12 December 2020

Increased levels of CD40-CD40 ligand system in patients with essential hypertension

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345621

1 reference

21 December 2017

1 reference

21 December 2017